Petros Pharmaceuticals In... (PTPI)
0.30
-0.01 (-3.38%)
At close: Jan 15, 2025, 10:32 AM
Company Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics.
The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease.
The company markets its line of ED products in the form of vacuum erection device products.
Petros Pharmaceuticals, Inc. is based in New York, New York.
Petros Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Dec 2, 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Fady Boctor M.B.A. |
Contact Details
Address: 1185 Avenue of the Americas New York, New York United States | |
| Website | https://www.petrospharma.com |
Stock Details
| Ticker Symbol | PTPI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001815903 |
| CUSIP Number | 71678J100 |
| ISIN Number | US71678J2096 |
| Employer ID | 85-1410058 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Fady Boctor M.B.A. | President & Chief Commercial Officer |
| Mitchell S. Arnold M.B.A. | Vice President of Finance & Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 8-K | Current Report |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 18, 2024 | DEFA14A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 25, 2024 | ARS | Filing |
| Oct 25, 2024 | DEF 14A | Filing |
| Oct 18, 2024 | 8-K | Current Report |
| Oct 17, 2024 | 8-K | Current Report |